THE JOHNS HOPKINS UNIVERSITY - A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
Key Details
Description
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
Context & Analysis
On Dec 8, 2025, Department of Health and Human Services obligated $4,617,504 to THE JOHNS HOPKINS UNIVERSITY for a phase ii, randomized, double-blind, placebo controlled trial to evaluate the antiviral activity, safety, and pharmacokinetics of novartis eyu688 against dengue virus 2 infection in a controlled huma…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: full and open competition. Performance is located in BALTIMORE, MD. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Related Opportunities
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.